Equities researchers at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Rating) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Pulmatrix in a research report on Tuesday, February 7th.
Pulmatrix Trading Down 3.8 %
Shares of PULM stock opened at $3.28 on Monday. Pulmatrix has a fifty-two week low of $3.16 and a fifty-two week high of $7.50. The business’s 50 day moving average price is $3.82 and its 200-day moving average price is $3.80.
Institutional Inflows and Outflows
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
- Get a free copy of the StockNews.com research report on Pulmatrix (PULM)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.